Background/Purpose:
The purpose of this study was to compare the sensitivity of the algorithms with and without ultrasound of the EULAR/ACR 2012 Classification Criteria for Polymyalgia rheumatica (PMR) to the former criteria in a retrospective single center study.
Methods:
All patients newly diagnosed with PMR at our tertiary rheumatology center between 01/2011 to 06/2012 were included in this retrospective study and analyzed whether the EULAR/ACR 2012 Classification Criteria for PMR with and without ultrasound as well as the formerly used PMR criteria (Bird & Wood’s, Chuang & Hunder’s, Healey’s, Jones & Hazelman’s) were fulfilled. All patients with suspected PMR underwent physical examination, questionaires, laboratory analysis, ultrasound examination of joints and an organ staging to exclude other conditions mimicking PMR (mostly laboratory analysis, chest X-ray and abdominal ultrasound examination).
Results:
PMR was established as a new diagnosis by a rheumatologist of our center in 35 patients between 01/2011 to 06/2012. The average age was 66.4 +/- 8.8 (mean +/- standard-deviation) years. 60.0% of those 35 patients were female. The average ESR before treatment was 43.0 +/- 24.6 mm/1h, the average CRP 43.8 +/- 31.6 mg/l, the average duration of morning stiffness 88.7 +/- 59.0 min. 82.9 % had hip pain or limited range of motion, 91.4 % had normal values for RF and ACPA and 34.3 % had no other joint involvement. We found that the sensitivity of the EULAR/ACR 2012 classification criteria for PMR without ultrasound was 88.6 %, the sensitivity of the algorithm with ultrasound was 82.9 %. We did not detect any patient fulfilling the classification criteria with ultrasound but not the criteria without ultrasound. The sensitivity of the formerly used criteria was 82.9 % for Bird & Wood’s, 40.0 % for Chuang & Hunder’s, 77.1 % for Healey’s and 82.9 % for Jones & Hazelman’s criteria.
Conclusion:
The results demonstrate a higher sensitivity of the novel EULAR/ACR criteria compared to the previous PMR classification criteria. However, ultrasound findings did not contribute to the higher sensitivity observed in our cohort of recent onset PMR patients.
Disclosure:
S. Balser,
None;
W. Hartung,
Abbott Immunology Pharmaceuticals,
5,
Pfizer Inc,
5;
E. LeBras,
None;
B. P. Ehrenstein,
Abbott Immunology Pharmaceuticals,
5,
Pfizer Inc,
5,
Roche Pharmaceuticals,
5;
M. Müller,
None;
M. Fleck,
Abbott Immunology Pharmaceuticals,
5,
Roche Pharmaceuticals,
5,
Pfizer Inc,
5.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-eularacr-2012-classification-criteria-for-polymyalgia-rheumatica-comparison-of-the-new-algorithms-with-and-without-ultrasound-to-the-formerly-used-criteria/